18th ANNUAL **2026** CONFERENCE

NNDC ANNUAL CONFERENCE SPONSORSHIP INFORMATION

Austin, TX | October 19-20, 2026

in collaboration with this year's host, The University of Texas at Austin Dell Medical School



Shaping the Future of Mood Disorders Care: Discovery, Innovation, and Collective Impact

NATIONAL NETWORK of DEPRESSION CENTERS

2723 South State Street, Suite 150, Ann Arbor MI 48104 | www.nndc.org

18th ANNUAL 2026 CONFERENCE

2026 NNDC Annual Conference Information

Austin, TX | October 19-20

Table of Contents

Welcome to the 2026 NNDC Annual Conference..... 1
Conference Sponsors..... 2
Power of the Network..... 3
NNDC Board of Directors..... 4
NNDC Staff..... 5
People Behind the Progress..... 6
Agenda..... 7-8
Biographies..... 9-13
Showing: Brainstorm..... 14
2026 Travel Awardees..... 15
Note of appreciation..... 16
Axsome Therapeutics Symposium Information..... 17-18
Myriad / GeneSight Symposium Information..... 19-20
Learner Information + Disclosures 21-23
How to Obtain Your Certificate..... 23
2026 Poster Submissions..... 24-29
Texas Union Floor Plans..... 30-31
Upcoming Events..... 32
Connect with us!..... 33

View each agenda by scanning the QR codes below:

October 19

October 20

NATIONAL NETWORK of DEPRESSION CENTERS

18th ANNUAL 2026 CONFERENCE

2026 NNDC Annual Conference Information

Austin, TX | October 19-20

Welcome to the 2026 NNDC Annual Conference!

Esteemed guests, colleagues, and friends,

It is with great pleasure that we welcome you to the 2025 NNDC Annual Conference. This year's theme is ***"Shaping the Future of Mood Disorders Care: Discovery, Innovation, and Collective Impact"*** and we're excited to discuss the evolving nature of our work. We're thrilled to gather and explore the groundbreaking advancements and innovative approaches that are transforming the landscape of mental health care.

This year's conference title embodies our mission to merge the rigorous methodologies of science, the transformative power of technology, and the essential human element of compassion. We are here to discuss, learn, and collaborate on innovative solutions that address the complexities of mental health in a holistic and inclusive manner.

With a robust agenda, we will hear from leading experts in the fields of neuroscience, psychiatry, psychology, and technology. We look forward to delving into cutting-edge research, examining new therapeutic technologies, and sharing best practices that have the potential to significantly improve the lives of those affected by mental health conditions.



Charles B. Nemeroff, MD, PhD Sagar Parikh, MD

This conference is a platform for building connections, fostering collaboration, and inspiring action. We are here to challenge conventional boundaries, question existing paradigms, and create a future where mental health care is accessible, effective, and compassionate for all.

We encourage you to engage actively, share your insights and reflect on the diverse perspectives that each of our participants brings. Together, we can pave the way for innovations that bridge science, technology, and compassion, making a tangible difference in mental health care.

Thank you for joining us on this important journey. Let's work together to transform these innovations in order to bring hope, healing, and humanity to all who need it.

In learning and collaboration,

Charles B. Nemeroff, MD, PhD Sagar Parikh, MD



From the NNDC Team

On behalf of the entire NNDC Team, we are pleased to welcome you to Austin, Texas for the 18th Annual Conference! Each year the conference program highlights the ways the NNDC is uniquely positioned to improve diagnosis and treatment of mood disorders by facilitating knowledge sharing across the nation and expediting next-generation research initiatives – and this year's program is no exception.

Our members are engaging in some of the most innovative and exciting innovation in the field, and the Annual Conference is a great way to connect over that work. We hope your time here is insightful and allows you to create connections to draw upon for years to come. Thank you for joining us and welcome to Austin!

NATIONAL NETWORK of DEPRESSION CENTERS

Thank you to our 2026 Sponsors!

Platinum Sponsors

axsome

genesight®

Myriad genetics®

Gold Sponsors

Otsuka

Supernus® Pharmaceuticals

Biogen

Silver Sponsors

Definium THERAPEUTICS


Johnson&Johnson

NEUROCRINE® BIOSCIENCES

Supporting Sponsor

Alkermes®

POWER OF THE NETWORK



LINDNER CENTER OF HOPE

EMORY UNIVERSITY

College of Human Medicine
MICHIGAN STATE UNIVERSITY

FSU | FLORIDA STATE UNIVERSITY

The University of Texas at Austin
Dell Medical School

JOHNS HOPKINS MEDICINE

Anschutz

Cleveland Clinic

UCDAVIS
UNIVERSITY OF CALIFORNIA

Stanford MEDICINE

Indiana University

Cincinnati Children's

UNIVERSIDAD AUTÓNOMA DE NUEVO LEÓN

PennState College of Medicine

VAN ANDEL INSTITUTE

MAYO CLINIC

IOWA

THE OHIO STATE UNIVERSITY

CINCINNATI

WESTERN MICHIGAN UNIVERSITY

Western Michigan University Homer Stryker M.D. SCHOOL OF MEDICINE

UIC UNIVERSITY OF ILLINOIS CHICAGO

PINE REST Christian Mental Health Services
pinerest.org

UNIVERSITY OF MICHIGAN

UNIVERSITY OF LOUISVILLE

Penn Medicine

UNC SCHOOL OF MEDICINE

THE UNIVERSITY OF NEW MEXICO

MEDICAL COLLEGE OF WISCONSIN

UTHealth Houston

RUSH UNIVERSITY

HEALTH UNIVERSITY OF UTAH

Weill Cornell Medicine

Mass General Brigham

UF UNIVERSITY of FLORIDA

NNDC Board of Directors

Executive Committee of the Board

Officers

Mark Frye, MD (President) • Mayo Clinic
Michelle Patriquin, PhD, ABPP (Vice President) • University of Texas Health Science Center at Houston
C. Neill Epperson, MD (Treasurer) • University of Colorado Anschutz Medical Campus
Melissa DelBello, MD, MS (Secretary) • University of Cincinnati, Lindner Center of HOPE & Cincinnati Children's
Olusola Ajilore, MD, PhD (Member-at-Large) • University of Illinois at Chicago
William Bobo, MD, MPH (Member-at-Large) • Florida State University
Faith Gunning, PhD (Member-at-Large) • Weill Cornell Medicine

Ex-Officio Members

J. Raymond DePaulo, Jr, MD (Immediate Past President) • The Johns Hopkins Mood Disorders Center
John F. Greden, MD (Founding Chair) • University of Michigan Eisenberg Family Depression Center
Stuart Charney, RPH, JD (Board Advisor) • NNDC Advisory Council

Center of Excellence Board Members

Caleb Adler, MD • University of Cincinnati, Lindner Center of HOPE & Cincinnati Children's
Jorge Almeida, MD, PhD • Dell Medical School at the University of Texas at Austin
William Bobo, MD, MPH • Florida State University
David Casey, MD • University of Louisville
Susan K. Conroy, MD, PhD • Indiana University
William Coryell, MD • University of Iowa
Mario Cristancho, MD • University of Pennsylvania
Alfredo Cuellar Barboza, MD • Autonomous University of Nuevo León
Dimitry Davydow, MD, MPH, FACLP • University of Florida
Joao de Quevedo, MD, PhD • University of Texas at Houston, McGovern Medical School
Marc Dubin, MD, PhD • Weill Cornell Medical College
Rif El-Mallakh, MD • University of Louisville Depression Center
Stefan Fernandez Zambrano, MD • Autonomous University of Nuevo León
Heather Flynn, PhD • Florida State University
Jay Fournier, PhD • The Ohio State University
Fernando Goes, MD • Johns Hopkins Medicine
Adriana Hermida, MD • Emory University
Richard Holbert, MD • University of Florida
Kay Redfield Jamison, PhD • Johns Hopkins University Mood Disorders Center
Jeremy Kendrick, MD • University of Utah Huntsman Mental Health Institute
Anand Kumar, MD, MHA • University of Illinois at Chicago
Scott Langenecker, PhD • The Ohio State University
Beth Lippard, PhD • Dell Medical School at the University of Texas Austin
Pamela Mahon, PhD • Mass General Brigham
Brian Mickey, MD, PhD • University of Utah Huntsman Mental Health Institute
Michelle Miller, PhD • Indiana University
Jeffrey Newport, MD, MS • Dell Medical School at the University of Texas Austin
Michael Ostacher, MD, MPH, MMSc • Stanford University
Sagar Parikh, MD, FRCPC • University of Michigan Eisenberg Family Depression Center
Michelle Patriquin, PhD, ABPP • University of Texas Health Science Center at Houston
Kristin Raj, MD • Stanford University
Scott L. Rauch, MD • Mass General Brigham
Patricio Riva Posse, MD • Emory University
Alan F. Schatzberg, MD • Stanford University
Christopher Schneck, MD • University of Colorado Anschutz Medical Campus
Michael Thase, MD • University of Pennsylvania
Carolyn Turvey, PhD • University of Iowa
Jennifer L. Vande Voort, MD • Mayo Clinic
Brendon Watson, MD, PhD • University of Michigan Eisenberg Family Depression Center

Board Members

Eric Achtyes, MD, MS • Western Michigan University Homer Stryker M.D. School of Medicine
Lena Brundin, MD, PhD • Van Andel Institute
Stephen Ferber, MD • Cleveland Clinic
Scott Gaynor, PhD • Western Michigan University
Marc Gunderson, MD • Medical College of Wisconsin
Louis Nykamp, MD • Pine Rest Christian Mental Health Services
Erika Saunders, MD • Penn State Milton S. Hershey Medical Center
Manpreet Singh, MD, MS • UC Davis
Patrick Sullivan, MD, FRANZCP • University of North Carolina at Chapel Hill
Mauricio Tohen, MD, DrPH, MBA • The Jan Fawcett Affective Disorders Memorial Center (UNM & Rush)
Nagy Youssef, MD, PhD • Michigan State University
John Zajecka, MD • The Jan Fawcett Affective Disorders Memorial Center (UNM & Rush)

About the Organization + NNDC Staff Members

The NNDC is a national network of world-class institutions and collaborators united to lift the burden of depression, bipolar and other mental health conditions to advance people's overall wellness. The organization works to transform people's lives through innovations in research, driving care solutions and advancing collective community impact.

Founded in 2008, the NNDC has since grown to 30+ members representing the top and most well-regarded psychiatry programs in the nation. Learn more at www.nndc.org.



Leadership + Contact Information



Dr. Matt Samocki
CEO
msamocki@nndc.org



Brad Hovermale
Director of Operations
bhovermale@nndc.org



Courtney Soule
Director of Membership, Development + Public Relations
csoule@nndc.org



Mary Laffey
Task Group Manager + Strategy Lead
mlaffey@nndc.org



Rob Vallentine
Strategic Business Advisor
rvallentine@nndc.org



Sagar Parikh, MD
Medical Director



Bailey Rann
Research + Media Specialist
brann@nndc.org

PEOPLE BEHIND THE PROGRESS

Stories of innovation, care and hope.



NATIONAL NETWORK *of* DEPRESSION CENTERS

About the Campaign

As champions of innovation, we know that every breakthrough begins with a person.

A researcher asking a new question. A clinician finding a better way to help a patient. A family member sharing hope. An advocate turning lived experience into action. A colleague reaching across institutions to solve a problem together.

These are the People Behind the Progress.

Join us for the NNDC's year-end giving campaign, People Behind the Progress: Stories of Innovation, Care and Hope, celebrating the people and ideas that are moving depression and bipolar disorder research, treatment and care forward.

Your donation helps support:

- Travel awards for emerging researchers and clinicians
- Momentum Grants
- Task Groups
- Events that advance professional connections
- Expanded CME opportunities
- Bolstering member partnerships + expanding membership
- The growth of the Mood Outcomes Program
- And much more!

Where to find:

Email, sent 1x per week via Constant Contact

Social media

Web (under "Give"): nndc.org/peoplebehindtheprogress/

Donate here:

https://nndc.org/donate

Shaping the Future of Mood Disorders Care: Discovery, Innovation, and Collective Impact

NNDC Conference Kickoff Summit - Monday, October 19, 2026

Time (CST)	Topic	Topic Description	Presenters	Location
11:30am-1:25pm	Registration and Lunch Buffet			Lobby and Shirley Bird Perry Ballroom (Catering Side)
Noon-2:25pm	Non-CME NNDC Task Group Member Open House (Drop-in)	An opportunity to meet NNDC Task Group members and learn more about the work being accomplished by the various groups. This promises to be a fun time with great conversation, collaboration and camaraderie. There will also be some private meeting space set aside for Task Groups that want to hold a more formal meeting.		Quadrangle Room
Concurrent Opportunities: Noon-1:25pm	From Community to Clinic: Scaling Evidence-Based Mental Health Impact Through Community Programs and Network Collaboration	This session will highlight how NNDC member sites engage communities through education, outreach, and partnerships beyond traditional clinical and academic settings. Speakers will discuss program impact, collaboration opportunities, fundraising potential, and how community engagement strengthens research, care, and public awareness.	Dr. Matt Mishkind Dr. Scott Langenecker Rob Vallentine	Shirley Bird Perry Ballroom (Conference side)
	BD²	This session will feature updates from the BD² Integrated Network, followed by short presentations highlighting early results and emerging questions from Network investigators. The talks will span topics including substance use disorder, bipolar depression, and response to drug treatment, providing a snapshot of how BD² data are being used to explore key questions in bipolar disorder research and care.	Dr. Mark Frye Dr. Emily Baxi Dr. Fernando Goes Dr. Jorge Almeida Dr. Balwinder Singh Dr. Elizabeth Lippard	Governor's Room
Concurrent Opportunities: 1:30-2:25pm	Public Education + NNDC Attendees Brainstorm screening and panel discussion	This event begins with a screening of BrainStorm, a 30-minute documentary that follows six individuals living with bipolar disorder while exploring the latest science on its causes and treatments. Following the film, panelists involved in the project will discuss the documentary's development, key themes, and the importance of advancing understanding of bipolar disorder. *This public education event is available to registered conference attendees and UT Austin students and faculty at no additional charge. Limited capacity of 200.*	Dr. Jorge Almeida Dr. Gabriel Fries Dr. Vijay Gorrepati Kimberly Allen Rob Vallentine	Texas Union Theatre (on 2nd Floor)
2:30-3:25pm	Myriad Genetics Panel Discussion & Workshop (Non-CME Independent Educational Session)	Advancing Access and Policy for Novel Approaches to Mood Disorders: A Join an interactive panel discussion on coverage, policy, and access challenges for personalized approaches to treating mood disorders. Through expert insights and a collaborative workshop, participants will explore strategies to navigate medical policy, improve reimbursement, and expand patient access to innovative care.	Dr. Ryan Griggs Dr. Stephen Ferber Ashley Svenson Kristin Fischer	Shirley Bird Perry Ballroom (Conference side)
	Optional Early Poster Session #1 Set Up	Poster presenters scheduled to present early on Day 1 are invited to use this time to set up their posters in advance, confirm placement, and address any setup needs before the evening poster session and the start of the conference program. Participation is optional, and presenters will receive setup instructions and details in advance.		Santa Rita Suite
3:30-4:55	Building Connection and Collaboration Across the NNDC Network	**Networking Opportunity (All NNDC Participants)** Connect with colleagues from across the NNDC network in a relaxed, informal setting. Whether you want to exchange ideas, discuss projects, explore collaborations, seek mentorship, or simply meet new people, this is an opportunity to make the most of the collective expertise and experience gathered at the conference.		Ballroom
		Testimonials Opportunity (All NNDC Participants) NNDC members are invited to stop by and record a brief video testimonial about their experience with the network and the impact of collaboration across NNDC. Recordings may be featured in NNDC's People Behind the Progress fundraising campaign.		Lone Star Room
		Mentorship Networking Session (Travel Awardees and Mentors Only) The session will connect mentors with NNDC Travel Award recipients from member sites. These individuals represent some of the most promising emerging professionals in our field and the future of the NNDC.		Quadrangle Room
Concurrent Opportunity: 4:00-4:55	NNDC Board of Directors in-person only Meeting			Governor's Room
5:00-5:55pm	Cocktail Hour & Optional Poster Presentation Session #1			**Cocktails:** Shirley Bird Perry Ballroom (Catering Side) **Posters:** Santa Rita Suite
6:00-7:30pm	Dinner Buffet and AI Panel Symposium (6:45-7:30pm)	A panel discussion exploring the opportunities and challenges of applying AI to real-world mental health data and research.	Dr. Peter Zandi Dr. Joanna Biernacka Dr. HongfangLiu	Shirley Bird Perry Ballroom (Catering + Conference side)

Closed Meetings (Invitation Only) - Monday, October 19, 2026

Time (CST)	Topic	Location
7am-11:55am	TRD Task Group	Lone Star Room
12:30-1:25pm	Strategic Partner Meeting #1	
1:30-2:25pm	Strategic Partner Meeting #2	

Shaping the Future of Mood Disorders Care: Discovery, Innovation, and Collective Impact

NNDC Academic Research Agenda – Tuesday, October 20, 2026

Time (CST)	Topic	Topic Title/Description	Speakers	Location
7:30-8:30am	Registration + Breakfast Buffet			Shirley Bird Perry Ballroom – Catering + Conference Side
8:30-8:55am	Welcome	Welcome Address, NNDC Administrative Updates and Special Recognition	NNDC Leadership	Shirley Bird Perry Ballroom
8:55-9:00am	Introduction	Opening Remarks	Dr. Claudia Lucchinetti University of Texas at Austin Dell Medical School	
9-9:30am	Symposium: Trauma, Depression, and the Life Cycle *Introductions by Dr. Heather Flynn*	**Paradise Lost: The Neurobiology of Child Abuse and Neglect** (25 min talk, 5 min Q&A)	Dr. Charlie Nemeroff University of Texas at Austin Dell Medical School	Shirley Bird Perry Ballroom
9:30-10am		**Neuropsychiatric Considerations in Hormonal Contraception** (25 min talk, 5 min Q&A)	Dr. Jeffrey Newport University of Texas at Austin Dell Medical School	
10-10:15am		**Panel Discussion with Audience Feedback** (15 min Q&A)	**Joining the panel:** Dr. Jeffrey Newport Moderator: Sagar Parikh, MD, FRCPC, University of Michigan, NNDC Medical Director	
10:15-10:30am	Break			
10:30-11am	Mini-Symposia 1: Technology-Driven Innovations in Mood Disorders Care	**Beyond Medication: The Emerging Role of Transcranial Magnetic Stimulation in Bipolar Depression** (25 min talk, 5 min Q&A)	Dr. Jorge Almeida University of Texas at Austin Dell Medical School	Shirley Bird Perry Ballroom
11-11:30am		**The Digital Advantage: Addressing Stigma and Bridging the Treatment Engagement Gap for Depression and Anxiety** (25 min talk, 5 min Q&A)	Dr. A. Pederson Mass General Brigham	
11:30-11:45am	Break			
11:45am-12:45pm	Lunch Options	General Conference Lunch		Shirley Bird Perry Ballroom – Catering or Conference Side
		Axsome Therapeutics Symposium (Non-CME Independent Educational Session)	Dr. Henry Nasrallah	
		Mood Outcomes Program Lunch Discussion (seating for dining up to 50)		Governor's Room
12:45-2:10pm	Poster Session			Santa Rita Suite
2:10-2:15pm	Transition Back for Afternoon Session			
2:15-2:30pm	Afternoon Kickoff	NNDC Administrative Announcements	NNDC Leadership	Shirley Bird Perry Ballroom
2:30-2:50pm	Hot Topics: Emerging Frontiers in Mood Disorders Science	**Untangling Depression: Novel Biological Subtypes of the Gut-Brain Axis** (15 min talk, 5 min Q&A)	Dr. Jane Foster University of Texas Southwestern	Shirley Bird Perry Ballroom
2:50-3:10pm		**Bipolar Disorder and Alcohol: Modifiable Targets to Move Towards Early Intervention and Better Outcomes** (15 min talk, 5 min Q&A)	Dr. Elizabeth Lippard University of Texas at Austin Dell Medical School	
3:10-3:30pm		**Single Session Interventions for Depression: RCT of 12 Digital Interventions** (15 min talk, 5 min Q&A)	Dr. Benjamin T. Kaveladze Dartmouth College	
3:30-3:45pm	Break			
3:45-4:45pm	Plenary Talk *Host welcome from Dr. Elizabeth Lippard*	**Mechanism-guided discovery of novel antidepressant treatments** (45 min talk, 15 min Q&A)	Dr. Conor Liston Weill Cornell Medicine	Shirley Bird Perry Ballroom
4:45-5pm	Break and optional poster pick up before 6pm			
5-5:30pm	Mini-Symposia 2: Transformative Therapeutics in Psychiatry	**Next Directions for Ketamine in Psychiatry** (25 min talk, 5 min Q&A)	Dr. Sanjay Matthew Texas A & M	Shirley Bird Perry Ballroom
5:30-6pm		**Do Psychedelics need Bespoke Psychotherapy to Work?** (25 min talk, 5 min Q&A)	Dr. Gregory Fonzo University of Texas at Austin Dell Medical School	
6-6:30pm	Networking Happy Half Hour			Shirley Bird Perry Ballroom – Catering + Conference Side
6:30-8:00pm	Dinner & Awards	Travel and poster awardees are celebrated		

Speaker Biographies

Plenary Speaker: Conor Liston, MD, PhD

Robert Michels, MD, Professor of Psychiatry
Vice Chair for Precision Psychiatry, Weill Cornell Medicine



Conor Liston, MD, PhD is the Robert Michels, MD, Professor of Psychiatry, a Professor of Neuroscience, and Director of the Institute for Precision Psychiatry at Weill Cornell Medicine. The long-term goals of his research program are to define basic mechanisms by which prefrontal cortical brain circuits support learning, memory, and motivation, and to understand how these functions are disrupted in depression, OCD, and other neuropsychiatric disorders. His team is also developing neuroimaging technologies for informing psychiatric diagnosis in human populations and predicting treatment response to transcranial magnetic stimulation and other forms of therapeutic neuromodulation.

Jorge R. C. Almeida, MD, PhD

Professor of Psychiatry and Behavior Sciences
Director, Bipolar Disorder Center, Dell Medical School at The University of Texas at Austin



Dr. Jorge R. C. de Almeida is Professor of Psychiatry and Behavioral Sciences at Dell Medical School at The University of Texas at Austin, where he directs the Bipolar Disorder Center at the Mulva Clinic for the Neurosciences. A board-certified psychiatrist, he has spent over two decades using neuroimaging to uncover the biology of bipolar disorder. He leads major research initiatives, including the BD² Integrated Network at UT Austin and an NIMH-funded study of neurodevelopmental risk in youth, and serves on the Board of Directors of the National Network of Depression Centers. He also co-chairs the Bipolar Disorder Workgroup within NNDC.

Elizabeth Thomas Cox Lippard, PhD

Associate Professor, Department of Psychiatry and Behavioral Sciences
Associate Director, Psychiatry Resident Research Track



Elizabeth Lippard is an associate professor of the Department of Psychiatry and Behavioral Sciences at Dell Medical School. Her research interests focus on the intersection of behavioral and developmental neuroscience. She studies how genetic vulnerability and environmental stress influence brain-behavior relationships across development, in clinical and typically developing populations. Her lab uses a combination of methods including multimodal magnetic resonance imaging (MRI) and placebo-controlled alcohol administration methodology. She takes a developmental approach, using longitudinal paradigms to identify neural circuitry, environmental, and behavioral predictors of alcohol misuse and mechanisms by which predictors translate into adult phenotypes (i.e., addiction) within and across mood disorders. Her lab also has a strong emphasis on the investigation of the role(s) of stress (acute, early life, and chronic exposure) in the development of comorbid alcohol and substance use disorders in mood disorders and related phenotypes (i.e. suicide).

Jane Foster, Phd

Professor, Department of Psychiatry, and the Center for Depression Research and Clinical Care at UT Southwestern Medical Center



As a neuroscientist and a leading expert on the microbiome, Dr. Foster's research aims to connect the dots between a person's 30 trillion gut microbes and their propensity for mental illness. Dr.Foster's research takes a 'bench to bedside' and back again approach to studying microbiota-brain and immune-brain systems aims to better understand the role of the gut-brain axis in both normal states and psychiatric disorders.

Gregory A. Fonzo, PhD

Associate Professor, Department of Psychiatry and Behavioral Sciences, UT Austin Dell Medical School
Co-Director, Charmaine & Gordon McGill Center for Psychedelic Research and Therapy



Dr. Fonzo's research focus spans the continuum of psychiatric disorder development to treatment and resolution. He has conducted work on computational and neurobiological mechanisms of affective symptoms in stress-related mental health disorders such as posttraumatic stress disorder, anxiety, and depression. He is also interested in understanding mechanisms and predictors of response to evidence-based treatments such as psychotherapy and antidepressant medication. More recently, he has initiated work on designing and establishing mechanisms and efficacy of novel neuroscience-informed interventions, with a particular focus on psychedelic therapies and neuromodulation. He has received several awards, including the One Mind Rising Star Award and the Brain and Behavior Research Foundation Young Investigator Award. His research on focused ultrasound neuromodulation was named a 2025 research achievement by the Brain & Behavior Research Foundation. His research is funded through the National Institutes of Health, several private foundations, and philanthropic gifts.

Benjamin T. Kaveladze, PhD

Postdoctoral Fellow, Center for Technology and Behavioral Health at Dartmouth College



Benjamin Kaveladze is a Postdoctoral Fellow in the Center for Technology and Behavioral Health at Dartmouth College, where he develops AI-enabled interventions to expand access to mental health support. His research focuses on designing and evaluating digital mental health tools that are both clinically effective and broadly appealing. He received his PhD in Psychology from UC Irvine and completed an NIH T32 fellowship at Northwestern University's Feinberg School of Medicine.

Sanjay J. Mathew, MD

Department Head and Professor, Robert A. Welch Chair in Psychiatry, Department of Psychiatry and Behavioral Sciences
Texas A&M University Naresh K. Vashist College of Medicine

Sanjay J. Mathew, M.D. is Professor and Department Head of Psychiatry and Behavioral Sciences at Texas A&M University Naresh K. Vashisht College of Medicine. He previously served as Vice Chair for Research at Baylor College of Medicine. He has devoted the last 25 years to research, education, and the clinical care of patients with severe, treatment-resistant mood disorders. The major impact of his team's work has been the development of novel drug therapy approaches for major depressive disorder, treatment-resistant depression (TRD), and related conditions (e.g., anxiety disorders and PTSD).



His work with ketamine has shed light on important questions such as the drug's impact on suicidal thinking, and how it might act in the brain. He was a leading investigator for a seminal trial which tested the effectiveness of ketamine compared to the most powerful intervention for TRD, electroconvulsive therapy. Currently, Dr. Mathew co-leads a large NIH-funded multicenter clinical trial which examines how to optimize the delivery of this rapidly-acting antidepressant in patients with TRD. His research has received widespread recognition, including receipt of a Brain and Behavior Research Foundation Distinguished Investigator Award, Alexander H. Glassman Memorial Award from the Department of Psychiatry at Columbia University, and the Gerald L. Klerman Senior Investigator Award from DBSA. He currently serves as the President of the Anxiety and Depression Association of America.

D. Jeffrey Newport, MD, MS, MDiv



Professor, Departments of Psychiatry & Behavioral Sciences and Women's Health
Associate Chair for Research, Department of Psychiatry & Behavioral Sciences
University of Texas at Austin Dell Medical School
Distinguished Teaching Professor, University of Texas System
Director, Women's Reproductive Mental Health of Texas
Director, Dell Med Psychiatry Physician-Scientist Training Program
Associate Director, Texas Childhood Trauma Research Network

D. Jeffrey Newport is Professor of Psychiatry and Women's Health at the University of Texas at Austin Dell Medical School where he serves as Associate Chair for Research for the Department of Psychiatry & Behavioral Sciences and Director of Women's Reproductive Mental Health of Texas. Dr. Newport completed a graduate theological degree before receiving his medical degree from the University of South Carolina. He subsequently completed psychiatric residency and a master's degree in clinical research at Emory University.

His awards include the NARSAD Independent and Young Investigator Awards, Young Faculty Award from the American Psychiatric Institute for Research and Education, the Society of Biological Psychiatry's Lilly Fellowship, the American College of Psychiatrists' Laughlin Fellowship, and the Distinguished Physician Alumnus Award from the University of South Carolina. He has published in leading journals across numerous specialties including JAMA, American Journal of Psychiatry, American Journal of Obstetrics & Gynecology, Neurology, and Pediatrics. Dr. Newport's research focuses on women's mental health with an emphasis on the psychobiology of perinatal psychiatric disorders, psychotropic pharmacokinetics during pregnancy and lactation, and the persistent biobehavioral impact of childhood trauma and other early life adverse experiences.

Charles Nemeroff, MD, PhD

Professor and Chair, Dell Medical School at The University of Texas at Austin



Charles B. Nemeroff is Chair and Professor with the Department of Psychiatry and Behavioral Sciences. He is co-director of the Charmaine and Gordon McGill Center for Psychedelic Research and Therapy and Director of the Institute for Early Life Adversity Research within the Department of Psychiatry and Behavioral Sciences as part of the Mulva Clinic for the Neurosciences. He received his medical degree and doctorate degrees in neurobiology from the University of North Carolina School of Medicine and completed his psychiatry residency training at UNC and Duke University. His research is focused on the pathophysiology of mood and anxiety disorders with a focus on the role of child abuse and neglect as a major risk factor. He has also conducted research on the role of mood disorders as a risk factor for major medical disorders including heart disease, diabetes and cancer. He has published more than 1,300 research reports and reviews, and his research is currently supported by grants from the National Institutes of Health.

Aderonke Bamgbose Bamgbose Pederson, MD

Assistant professor of psychiatry, Massachusetts General Brigham-Harvard University

Aderonke Pederson, MD, is an Assistant Professor at Harvard Medical School and a psychiatrist at Massachusetts General Brigham Academic Medical Center (MGB AMC). She practices within the Depression Clinical Research Program at Massachusetts General Hospital, focusing on patients with treatment-resistant depression. Dr. Pederson directs the Stigma Lab, where she leads clinical trials developing interventions to improve mental health service engagement among those who need treatment but remain disengaged. Her research examines medical mistrust, mental illness stigma, and health disparities affecting underserved and vulnerable populations. She has received five federal grants, including an NIH/NIMH Career Development Award (K23), and serves as vice chair of MGB's Institutional Review Board.



Recognized nationally, Dr. Pederson has published op-eds in The Washington Post, The Hill, and The Grio, and presented her work at university grand rounds and forums hosted by the National Institute on Aging, Medscape, and Apple. She has also mentored more than 20 scholars from underrepresented backgrounds, supporting their professional development and research publications.

Host & Moderator Biographies

Host Chair: Claudia F. Lucchinetti, M.D.
Executive Vice President for Medical Affairs and the UT Dell Medicine Health System, The University of Texas at Austin
Dean, Dell Medical School
Frank and Charmaine Denius Distinguished Dean's Chair in Medical Leadership
Professor, Department of Neurology

Claudia F. Lucchinetti, M.D., is executive vice president for medical affairs at The University of Texas at Austin, dean of Dell Medical School and the executive leader of UT Dell Medicine, UT's academic health system. In these roles, she oversees Dell Med's work in education, research and clinical care, including operations at UT Health Austin, Dell Med's clinical practice, and leads the University's comprehensive health care strategy. She also holds the Frank and Charmaine Denius Distinguished Dean's Chair in Medical Leadership.

A neurologist with specialization in neuroimmunology and experimental neuropathy, she is an internationally recognized expert in the clinical and neuropathological underpinnings of the broad spectrum of inflammatory demyelinating diseases, including multiple sclerosis, neuromyelitis optica and MOG antibody associated disease.

Lucchinetti comes to Austin from Mayo Clinic in Rochester, Minnesota, where she was dean of clinical and translational science and director of the Center for Clinical and Translational Science. She also served as chair of the Department of Neurology and chair of the neurology enterprise subspecialty council, where she oversaw strategic and operational responsibilities across Mayo Clinic sites nationwide. She was the Eugene and Marcia Applebaum Professor of Neurosciences at Mayo Clinic Alix School of Medicine, where she remains a professor of neurology. Additionally, she served on the Mayo Clinic board of governors and board of trustees.

She earned her medical degree from Rush Medical College in Chicago and, after an internship at Rush-Presbyterian-St. Luke's Medical Center, completed a neurology residency and a fellowship in neuroimmunology at Mayo Clinic College of Medicine and Science. As a Mayo Foundation Scholar, she trained in experimental neuropathology with Hans Lassmann, M.D., at the Brain Research Institute in Vienna, Austria.

Lucchinetti's research contributions include a landmark study describing four patterns of tissue damage in early multiple sclerosis; it suggested that MS lesions form differently among patient subgroups. This work markedly refined medicine's understanding of the disease, indicating the potential for individualized therapy based on pathological subtype.

Following paradigm-changing research that found evidence for early inflammatory cortical damage in MS, Lucchinetti was the first to propose that the disease progresses from the outermost layers of the brain before extending into deeper regions. As a result, scientists and physicians better understand the sequence and timing of damage to the nervous system resulting from MS, leading to novel imaging biomarkers of the disease and new treatment strategies.

She was also first to propose that based on pathology, neuromyelitis optica, a condition where the immune system damages the spinal cord and the nerves of the eyes, was an antibody-mediated disease targeting the perivascular space and, with a team of Mayo collaborators led by Vanda Lennon, M.D., identified the first biomarker targeting the water channel expressed on astrocytes, a subtype of glial cells. These and subsequent studies have reshaped our understanding of neuromyelitis optica and its relationship to MS and opened a field of research into the roles of astrocytes in the central nervous system.

Lucchinetti has been the recipient of significant research grant funding from the National Multiple Sclerosis Society, the National Institute of Neurological Disorders and Stroke, the National Center for Advancing Translational Sciences and the U.S. Department of Defense. She is also on the Council of the National Institute of Neurological Disorders and Stroke and the recipient of numerous awards, including the 2016 John Dystel Prize for MS Research.

To date, she has authored more than 220 peer-reviewed articles, with an h-index of 88.



Host & Moderator Biographies

Moderator: Heather Flynn, PhD

Professor and Chair, Department of Behavioral Sciences and Social Medicine

Heather A. Flynn, Ph.D. is a Professor at the Florida State University (FSU), College of Medicine and Chair of the Department of Behavioral Sciences and Social Medicine. She is Director of the FSU Center for Behavioral Health Integration. Dr. Flynn received her doctorate in clinical psychology from Florida State University, and completed a mental health and substance use fellowship at the University of Michigan Medical School in 1998. She served on the faculty at the UM Department of Psychiatry from 1998-2011, where she co-founded the UM Women and Infants Mental Health Program. Dr. Flynn's research is focused on improved identification, treatment and outcomes for behavioral health disorders, with a particular focus on women and children. As a clinical psychologist, she has worked for over 25 years as a clinician, researcher and trainer in the behavioral health field. Her work is specifically aimed at developing and testing for behavioral health in medical and community settings. Dr. Flynn is also involved in statewide, national and international work on improving behavioral health approaches and outcomes.




She is the Co-Chair of the Florida Maternal Mental Health Collaborative, and the Chair of the Women & Mood Disorders Task Group within the National Network of Depression Centers. She has worked with teams to develop international quality standards by implementing processes for practitioner and trainer / supervisor certifications in evidence-based behavioral health treatments including Motivational Interviewing and Interpersonal Psychotherapy. In 2018, Dr. Flynn was appointed to serve on the Florida Governors Mental Health Task Force. She also served as a member of the Florida Statewide Suicide Prevention Task Force, and in 2020 was appointed to the Florida Governors Opioid Task Force. Dr. Flynn is passionate about community-partnered, collaborative work aimed at improving mental health and substance use for families in the US and around the world.

Moderator: Sagar Parikh

John F. Greden Professor of Depression and Clinical Neuroscience, University of Michigan
Professor of Psychiatry and Program Director, Unipolar Psychiatry

Sagar V. Parikh, M.D., FRCPC is the John F. Greden Professor of Depression and Clinical Neuroscience at Michigan Medicine at the University of Michigan, Ann Arbor. His passion: to use every tool in the toolbox to improve health. Central to that function is experience in multiple roles and directions. His educational experiences include growing up in Canada, high school at Andover in Massachusetts, a gap year in India studying philosophy and yoga, bioengineering at Columbia University in New York, medical school and internship at McGill University in Montreal, followed by several years of working as a primary care doctor in rural northern Manitoba, as well as later in Toronto. Psychiatric training followed, including residency and research training at the University of Toronto, where he became Professor of Psychiatry and Deputy Psychiatrist-in-Chief at the University Health Network. He moved to the University of Michigan in 2015.
He focuses on mood disorder interventions of all types: service delivery design, medications, psychotherapy, digital tools, ketamine, TMS, and medical education research. He is the Medical Director of the National Network of Depression Centers (USA) and Education Chair of the Canadian Network of Mood and Anxiety Treatments (CANMAT).

Dr. Parikh has authored or edited three books and more than 200 peer-reviewed articles and book chapters. He co-authored all 12 editions (1997–2024) of the C CANMAT treatment guidelines for depression and bipolar disorder. His numerous honors include awards for psychiatric education and research, including the APA's Academic Gold Award for Psychiatric Services Achievement (2019) and the International Society for Bipolar Disorders' Mogens Schou Award for Education and Teaching (2020).



He co-chairs CAN-BIND's Community Advisory Committee, comprising 15 individuals with lived experience of mood disorders, which helps guide the network's research and educational priorities. He also leads CAN-BIND's Knowledge Translation Platform, translating research into public action. Most recently, he has partnered with the Depression and Bipolar Support Alliance to advance care and advocacy for people with mood disorders.



FILM SCREENING + PANEL DISCUSSION

This public education event is available to registered conference attendees and UT Austin students and faculty at no additional charge.

BRAINSTORM
Transforming the Bipolar Landscape

About the Film

***BrainStorm* follows six compelling people living with bipolar in their journey from devastation to recovery.** The film connects their experiences with the latest bipolar brain science to shed light on potential causes and successful treatments.

Through the stories, we learn that bipolarity exists on a spectrum, that two out of three people with bipolar do not exhibit classic signs of mania and, as a result, are consistently misdiagnosed. Yet when properly diagnosed and treated, they can and do live full, rich — and even extraordinary — lives.

BrainStorm opens up a timely and crucial conversation about diagnosis and treatment to **save lives, maximize healing, and end stigma** for millions of people around the globe who live with bipolar, and all those who love them.

Mon. Oct. 19
1:30-2:30 PM
Texas Union Building Theatre (2nd Floor)

No RSVP necessary, but capacity is limited to 200 people.

Panelists:
Dr. Gabriel Fries – UT Austin Researcher
Dr. Jorge Almeida – UT Austin Clinician
Dr. Vijay Gorrepati – UT Austin Clinician
Kimberly Allen - DBSA
Rob Vallenine - NNDC Moderator

"BrainStorm is truly a magnificent documentary. The film educates, inspires, and fosters empathy while advancing public understanding of one of psychiatry's most complex illnesses."

— DR. HOLLY SWARTZ
PRESIDENT, INTERNATIONAL SOCIETY FOR BIPOLAR DISORDERS

18th ANNUAL **2026** CONFERENCE

FILM SHOWING AT THE

NNDC ANNUAL CONFERENCE

Shaping the Future of Mood Disorders Care: Discovery, Innovation, and Collective Impact

NNDC Annual Conference Information

The University of Texas at Austin Dell Medical School

NATIONAL NETWORK *of* DEPRESSION CENTERS

2723 South State Street, Suite 150, Ann Arbor MI 48104 | www.nndc.org

2026 NNDC Annual Conference Young Investigator Travel Awardees

The NNDC is pleased to offer up to 10 Young Investigator Travel Awards of $1,000 each to eligible conference attendees who present a poster at the NNDC Annual Conference. This award can be used to cover travel costs associated with attending the conference, including airfare, hotel, ground transportation, parking, and mileage, as appropriate.

The NNDC Young Investigator Travel Awards provide support for outstanding early-career researchers and clinicians presenting their work at the Annual Conference. Recipients were selected through a competitive review process that evaluated research quality, career development potential, financial need, and the anticipated impact of conference participation. We congratulate this year's awardees and are pleased to support their continued growth and contributions to the field of mood disorders research and care.





Chloe Venter, MD Student
Florida State University



Feyza Yaylaci, MD
Mayo Clinic



Hossam Ali, MD
Mayo Clinic



Jake Branchini, Medical Student
UC Davis



Jeremiah Joyce, MD, MS
Mayo Clinic



Manuel Gardea Resendez, MD
Universidad Autónoma de Nuevo León



Salih Cayir, MD
UTHealth Houston



Simon Shugar, BS
University of Florida Health



Sooan Kim, PharmD, MS
Mayo Clinic



Umair Bhutto, MD
University of Louisville Depression Center

Thank you: We are profoundly grateful for all of your support!

The National Network of Depression Centers extends its sincere gratitude to everyone who contributed to the success of the 2026 Annual Conference.

We thank the leadership, faculty, staff, and students of **UT Austin Dell Medical School** for their partnership and hospitality; **our sponsors** for their generous support; and **our attendees** and **NNDC members** whose engagement and collaboration make this community possible.

We are especially grateful to the **many volunteers** who dedicated countless hours behind the scenes to develop this conference, including the **Annual Conference Program Committee**, **Young Investigator Travel Award Committee**, **Poster Award Committee**, **Young Investigator Mentors**, and the many **speakers**, **presenters**, **panelists**, **moderators**, and **poster presenter**s who shared their expertise and helped advance the field.

Special appreciation is extended to the volunteers who reviewed travel and poster award applications. Through a rigorous review process modeled on NIH peer-review principles, committee members evaluated applications using established criteria and abstained when conflicts of interest could affect impartiality, helping ensure a fair and transparent selection process.

We also thank the **Brainstorm Team**, **UT Austin Dell Medical School Staff Support**, **Texas Union Staff**, **40 Acres Catering**, and **Convention Handling Services** for their professionalism and support throughout the planning and execution of this event.

Finally, we recognize the dedication of **NNDC Leadership**, **Task Group members**, **Mood Outcomes Program sites and steering committe**e, **committee members**, **mentors**, **reviewers**, and **volunteers across the Network**. This conference would not be possible without their generosity, commitment, and many hours of service in support of NNDC's mission and educational programs.

Thank you for helping shape the future of mood disorders care through discovery, innovation, and collective impact.

Axsome Therapeutics Sponsored Symposium
(Non-CME Independent Educational Session)

October 20, 2026 | 11:45-12:45 PM CST | Ballroom

Glutamate: The Neurotransmitter at the Nexus of Psychiatry

This symposium explores the critical role of glutamate in brain function and psychiatric illness. The presentation reviews glutamate's involvement in learning, memory, cognition, and mood, explores how disruptions in glutamatergic signaling contribute to psychiatric disorders, and discusses emerging treatments that target the glutamate system, including NMDA receptor antagonists and their effects on neuroplasticity and synaptogenesis.



Henry Nasrallah, MD
Speaker
University of Cincinnati College of Medicine

Axsome Therapeutics Sponsored Symposium
(Non-CME Independent Educational Session)



Henry Nasrallah, MD
Vice Chair for Faculty Development and Mentorship
Professor of Psychiatry, Neurology, & Neuroscience
Director, Neuropsychiatry and Schizophrenia Programs
Director, Psychiatry CME Programs
University of Cincinnati College of Medicine

Dr. Henry Nasrallah is a widely recognized neuropsychiatrist, educator and researcher. Following his psychiatric residency at the University of Rochester, and neuroscience fellowship at the NIH, he served for 12 years as chair of psychiatry at The Ohio State University and 6 years as chair of psychiatry and neurology at St. Louis University, followed by 4 years as Associate Dean. He is currently Professor of Psychiatry, Neurology and Neuroscience, Medical Director of Neuropsychiatry Program and Director of the Schizophrenia Program in the Department of Psychiatry and Behavioral Neuroscience at the University of Cincinnati College of Medicine.

Dr. Nasrallah has published 14 books, 720 scientific articles and 650 abstracts. He is the founder and Editor-In-Chief of 3 scientific journals. He is a Fellow of the American College of Neuropsychopharmacology, Fellow of the American College of Psychiatrists, Distinguished Fellow of the APA, Fellow of the American Society of Clinical Psychopharmacology, Founder of the global Schizophrenia Society SIRS, and Founder of the nonprofit Foundation CURESZ. He served as president of 6 scientific societies and has received 43 research and teaching awards. He ranks in the top 1% of the world's researchers in terms of his publications being cited. He has received 95 research grants and has been elected annually to the list of "Best Doctors in America".

Myriad genetics®

genesight®

Myriad Genetics/Genesight Sponsored Panel + Workshop (Non-CME Independent Educational Session)

October 19, 2026 | 2:30-3:25 PM CST | Ballroom

Advancing Access and Policy for Novel Approaches to Mood Disorders: A Panel Discussion & Workshop

This interactive workshop will bring together NNDC members interested in addressing access, policy, and implementation challenges related to novel mood disorder treatments. Following a brief presentation on psychiatric pharmacogenomic testing coverage, attendees will participate in a moderated discussion on strategies to improve patient access, health system adoption, and reimbursement for innovative treatment approaches.

Hosted by leaders from Myriad Genetics and the NNDC Access and Care Delivery Task Group, this session is open to all attendees interested in collaborative problem-solving and cross-site dialogue on access and policy.



Ryan Griggs, PhD, MS
Co-Moderator
Genesight | Myriad Genetics



Stephen Ferber, MD
Co-Moderator
Cleveland Clinic



Ashley Svenson, MS, GC
Panelist
Myriad Genetics



Kristin Fischer, MBA, MA
Panelist
Myriad Genetics

Give us your feedback!

Anonymous Evaluation Link

Myriad Genetics/Genesight Sponsored Panel + Workshop (Non-CME Independent Educational Session)

CO-MODERATOR | Ryan Griggs, PhD, MS

Senior Medical Science Liaison, Myriad Genetics

As a Senior Medical Science Liaison with GeneSight at Myriad Genetics, Ryan's mission is to empower mental health treatment by serving as a clinical and scientific resource for clinicians and fostering partnerships with the research and healthcare communities. Ryan strives to achieve better outcomes for patients by delivering educational presentations, consulting with clinicians, and leading collaborative research projects that advance the science and knowledge of pharmacogenomics. Prior to Myriad, Ryan worked in drug discovery at Merck, taught at several academic institutions in the Ohio/Kentucky region, and led diverse teams of international neuroscientists as a PhD and postdoctoral researcher. Ryan holds a bachelor's degree in biomedical science from Drexel University, a master's degree in biotechnology from the University of Pennsylvania, and a doctorate in neurophysiology from the University of Kentucky. He enjoys playing sand volleyball and spending time with his wife, two young children, and dogs Waylon and Darling in Dayton, Ohio.

CO-MODERATOR | Stephen Ferber, MD

Assistant Director - The Psychiatric Treatment-Resistance Program, Cleveland Clinic

Dr. Stephen Ferber currently serves as the Assistant Director of The Psychiatric Treatment-Resistance Program at Cleveland Clinic. He has extensive experience in the management of treatment-resistant mental health conditions, specializing in interventional psychiatry with a focus on Transcranial Magnetic Stimulation (TMS), Ketamine, and Electroconvulsive Therapy (ECT). Dr. Ferber's research has focused on targeting strategies in TMS, and he maintains active membership in the International Society for ECT and Neurostimulation as well as the Clinical TMS Society. He has also devoted significant time to medical student and residency education, developing numerous didactics and electives focusing on circuit-based care and the utilization of the primary interventional modalities.

PANELIST | Ashley Svenson, MS, GC

Medical Policy Director, Myriad Genetics

Ashley Svenson, MS, CGC is a Medical Policy Director at Myriad Genetics, with a focus on advancing medical policies for national health plans and state Medicaid programs by leveraging published evidence, guidelines, coalitions, legislation, and advocacy. Ashley received her Master of Science degree in Genetic Counseling from Mount Sinai School of Medicine in 2003. Prior to moving to the laboratory industry, she practiced as a clinical genetic counselor for over a decade. She is an active member of the Texas Society of Genetic Counselors (TSGC) and the National Society of Genetic Counselors (NSGC) where she served as Practice Guideline Committee Chair.

PANELIST | Kristin Fischer, MBA, MA

Associate Director of Regional Accounts, Myriad Genetics

AsKristin Fischer is an Associate Director of Regional Accounts at Myriad Genetics, where she leads strategic partnerships with Blue Cross Blue Shield and regional health plans to advance coverage and reimbursement for Myriad's genetic testing portfolio. Since joining Myriad's Payer Markets team in 2017, she has helped expand patient access to testing across key regional markets. Prior to Myriad, Kristin worked in global marketing at Eli Lilly and managed public health initiatives in underserved rurastl communities throughout Latin America. She holds both an MBA and MA from The University of Texas at Austin and continues to call Austin home.

Learner Notification

National Network of Depressions Centers
2026 NNDC 18th Annual Conference
October 19-20, 2026
Austin, Texas

Acknowledgement of Financial Commercial Support
No financial commercial support was received for this educational activity.

Acknowledgement of In-Kind Commercial Support
No in-kind commercial support was receivedfor this educational activity.

Satisfactory Completion
Learners must complete an evaluation form to receive a certificate of completion. Your chosen sessions must be attended in their entirety. If you are seeking continuing education credit for a specialty not listed below, it is your responsibility to contact your licensing/certification board to determine course eligibility for your licensing/certification requirement.

Joint Accreditation Statement

JOINTLY ACCREDITED PROVIDER™ INTERPROFESSIONAL CONTINUING EDUCATION

In support of improving patient care, this activity has been planned and implemented by Amedco LLC and National Network of Depressions Centers. Amedco LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Amedco Joint Accreditation Provider Number: 4008163
Professions in scope for this activity are listed below.

Physicians
Amedco LLC designates this live activity for a maximum of 6.0 AMA PRA Category 1 Credits™ for physicians. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses
Amedco LLC designates this activity for a maximum of 5.0 ANCC contact hours.

Psychologists

AMERICAN PSYCHOLOGICAL ASSOCIATION

This course is co-sponsored by Amedco and National Network of Depressions Centers. Amedco is approved by the American Psychological Association to sponsor continuing education for psychologists. Amedco maintains responsibility for this program and content. Maximum of 5.00 hours.

The following state boards accept courses from APA providers for Psychologists/Counselors: AK, AR, AZ, CA, CO, CT, DC, DE, FL, GA, HI, IA, ID, IL, IN, KS, KY, MA, ME, MN, MO, NC, ND, NH, NE, NJ, NM, NV, OH, OK*, OR, PA, RI, SC, SD, TN, TX, UT, VA, WA, WI, WY
MA: Accepts APA for all classes of psychology license; does not accept APA for licensed counselors(LMHC, LMFT, etc.) except LEP.
MD: Does not accept Jointly Accredited content.
MI: Accepts courses from APA for Psychologists. No general CE requirement for Counselors.
OK: Accepts APA credit for live, in-person activities but not for ethics and/or online courses.
The following state boards accept courses from APA providers for MFTs: AK, AR, AZ, CA, CO, CT, DE, FL, GA, IA, ID, IN, KS, MD, ME, MO, NE, NC, NH, NJ, NM, NV, OH, OK*, OR, PA, RI, SC, SD, TN, TX, UT, VA, WA, WDC, WI, WY
AL MFTs: Credits authorized by NBCC or any other state licensing agency will be accepted.
MA MFTs: Participants can self-submit coursesnot approved by the MAMFTboard for review.
MI MFTs: There are no CE requirements for MFTs in MI.
The following state boards accept courses from APA providers for Addictions Professionals: AK, AR, CO, CT, DC, DE, GA, IA, IN, KS, LA, MD, MO, MT, NC, ND, NE, NJ, NM, NY (held outside NY ONLY), OK*, OR, SC, UT, WA, WI, WY
The following state boards accept courses from APA providers for Social Workers: AK, AR, AZ, CA, CO, DE, FL, GA, ID, IN, KY, ME, MN, MO, NE, NH, NM, OR, PA, VT, WI, WY

Learner Notification

Social Workers

As a Jointly Accredited Organization, Amedco is approved to offer social work continuing education by the Association of Social Work Boards (ASWB) Approved Continuing Education (ACE) program. Organizations, not individual courses, are approved under this program. State and provincial regulatory boards have the final authority to determine whether an individual course may be accepted for continuing education credit. Amedco maintains responsibility for this course. ASWB Content Level: Intermediate/Advanced. Social workers completing this course receive up to 6.0 continuing education credits.

The following state boards accept courses offering ASWB ACE credit for Social Workers: AK, AL, AR, AZ, CA, CO, CT, DC, DE, FL, GA, HI, ID, IL, IN, IA, KS, KY, LA, ME, MD, MA, MI, MN, MS, MO, MT, NC, ND, NE, NH, NM, NJ, NV, OH, OK*, OR, PA, RI, SC, SD, TN, TX, UT, VT, VA, WA, WI, WV*, WY
OK: Accepts ASWB ACE for live, in-person activities but not for ethics and/or online courses.
WV: Accepts ASWB ACE unless activity is held live in West Virginia.
The following state boards accept courses offering ASWB ACE credit for Counselors: AK, AR, AZ, CA, CO, CT, DC, FL, GA, IA, ID, IL, IN, KS, MA (LEP ONLY),MD, ME, MO, ND, NE, NM, NH, NV, OK*, OR, PA, TN, TX, UT, VA, WI, WY
MI: No CE requirement for licensed counselors.
The following state boards accept courses offering ASWB ACE credit for MFTs: AK, AR, AZ, CA, CO, FL, IA, ID, IN, KS, MD, ME, MO, NC, NE, NH, NM, NV, OK*, OR, PA, RI, TN, TX, UT, VA, WI, WY
AL MFTs: Credits authorized by NBCC or any other state licensing agency will be accepted. MA MFTs: Participants can self-submit courses not approved by the MAMFT board for review. MI: No CE for requirement for licensed MFTs.
The following state boards accept ASWB ACE credit for Addictions Professionals: AK, CA, CO, CT, GA, IA, IN, KS, LA, MO, MT, ND, NM, NV, OK, OR, SC, WA, WI, WV, WY

Objectives: After Attending This Program You Should Be Able To

1. Evaluate emerging neurobiological mechanisms and biomarkers underlying depression and bipolar disorder to inform development of novel pharmacologic and neuromodulation treatments.
2. Apply evidence-based and novel interventions, includingneuromodulation and pharmacologic treatments, in clinical practice.
3. Integrate current research on developmental, biological, and environmental factors into the assessment and treatment of mood disorders.

Disclosure of Conflict of Interest

The following table of disclosure information is provided to learners and contains the relevant financial relationships that each individual in a position to control the content disclosed to Amedco. All of these relationships were treated as a conflict of interest, and have been resolved. (C7 SCS 6.1-6.2, 6.5)

All individuals in a position to control the content of CE are listed below.

Name	Commercial Interest:Relationship
Jorge Almeida	NA
Bill Bobo	NA
Laura Cabrera	NA
Paul Carlson	NA
Alison Engbretson	NA
Greg Fonzo	Alto Neuroscience: Stock Shareholder SynapseBio AI: Consultant
Jane Foster	NA
Mark Frye	Myriad: Research Grant Overall Principal Investigator Baszucki Group: Research Grant Site Principal Investigator BD2:Consultant
Marie Gaine	American Physician Institute, Carnot Laboratories, Chymia LLC: Other
Brad Hovermale	NA
Benjamin Kaveladze	NA

Learner Notification, conflict of interest, cont.

Name	Commercial Interest:Relationship
Mary Laffey	NA
Elizabeth Lippard	NA
Conor Liston	NA
Devon LoParo	NA
Sanjay Matthew	AtaiBeckley, Autobahn Therapeutics, Aytu Biopharma, Definium, Douglas, Engrail, Freedom Biosciences, Motif Neurotech, Neumora, Newleos, Sensorium, Supernus, Syndeio, Xenon: Consultant Abbott:ResearchGrant Site Principal Investigator
Leslie Miller	NA
Charles Nemeroff	National Institutes of Health: Research Grant Overall Principal Investigator Compounds, Compositions, Methods of Synthesis, and Methods of Treatment (CRF Receptor Binding Ligand) (US 8,551, 996 B2), Method and devices for transdermal delivery of lithium (US 6,375,990B1), Method of assessing antidepressant drug therapy via transport inhibition of monoamine neurotransmitters by ex vivo assay (US 7,148,027B2):Patent Holder Abbott Laboratories Engrail Therapeutics Galen Mental Health, LLC Senseye, Inc Precisement Health Autobahn Therapeutics, Inc EMA Wellness Denovo BioPharma LLC Acadia Alvogen Reunion Neuroscie, ANeuroTech (division Anima BV) (paused 08/31/2025) X SignantHealth – Ends 6/21/2024 X Janssen Research & Development LLC, (ended 3/2025) BioXcel Therapeutics (ended 2024) X Silo Pharma – Ended 09/01/, EmbarkNeuro (formerly AncoraBio) – Ended 11/01/2024 X Goodcap Pharmaceuticals Inc – Termination submitted 10/2025 X ITI, Inc – Ended 05/2025 X LUCY Scientific Discovery (ended 12/31/2024) X Relmada Th, Skyland Trails (Ended 12/31/2024) X Patient Square Capital, LP X Ended 05/2026:Consultant Laureate Institute for Brain Research (LIBR), Inc Galen Mental Health, LLC Senseye, Inc Denovo Biopharma LLC Wave Neuroscience Invisalert Solutions Inc Incannex Healthcare Inc Bluecarta Inc, Sage Therapeutics, Inc Ended 2/20/2026 ANeuroTech (Division Anima BV) Ended 09/2025 Signant Health – Ends 6/21/2024 Skyland Trail (ended 2/24):Scientific/Medical Advisory Board Member Corcept Therapeutics Company EMA Wellness Precisement Health Relmada Therapeutics, Inc Signant Health Galen Mental Health Senseye Kivira Health Inc Denovo Biopharma LLC Headlamp Health Inc Bluecarta I:Stock Shareholder
Jeffrey Newport	Magnus Medical:Research Grant Site Principal Investigator Sage Therapeutics/Supernus Pharmaceuticals:Research Grant Overall Principal Investigator
Sagar Parikh	Otsuka, Biogen,Almatica, Boehringer Ingelheim:Consultant Janssen, Compass, Alto Neuroscience:Research Grant Site Principal Investigator
Aderonke Pederson	Otsuka:Consultant
Bailey Rann	NA
Erin Richardson	NurturedTX:Corporate Board Member Sage Therapeutics:Other Texas Child Mental Health Consortium:Research Grant Site Principal Investigator Rand Institute/NIMH Funded Research Study, Senseye:Scientific/Medical Advisory Board Member
Francisco Romo-Nava	Axsome:Scientific/Medical Advisory Board Member NIMH:Research Grant OverallPrincipal Investigator USPTO Patent:Patent Holder
Matt Samocki	NA
Giselli Scaini	NA
Courtney Soule	NA
Rob Vallentine	**NA**
Jeni Wade	NA
Dana Mortenson	NA

OBTAIN YOUR CERTIFICATE HERE!

How to Get Your Certificate

1. Go to nndc.cmecertificateonline.com
2. Click on the **2026 NNDC 18th Annual Conference link**.
   a. This link will remain available from October 20, 2026 through January 20, 2027
3. Evaluate the meeting.
4. Print, download, or save your certificate for your records.
5. If you lose your certificate, or need help, go to help.cmecertificateonline.com

Copyright © 2015 Amedco - 90 W Country Road C Suite 300 St. Paul, Minnesota 55117 | 651-487-3001 Office | 651-789-6606 Fax

Annual Conference Poster Session

The posters listed below were submitted in the following categories:

Basic Science

All areas of research are welcome, especially projects exploring biological or psychosocial approaches to understanding mood disorders, new or repurposed treatments and technologies, monitoring strategies that may improve patient outcomes, or objective measures such as biometrics, neuroimaging, bloodwork, or genetics. Projects may also choose to highlight the translational potential of their findings—for example, how basic discoveries could inform future diagnostic tools, treatment development, or pathways toward clinical application.

Clinical Programs

Unified efforts are essential for advancing technological innovation, disseminating new information, and enhancing clinical practice. Posters in this category may showcase multidisciplinary programs, demonstrate effective collaborations beyond academic boundaries, or address clinical assessments such as patient questionnaires, clinical diagnoses, or clinical interviews. Presenters may also describe how their clinical programs support translational research by applying emerging evidence to real-world care, evaluating feasibility of new tools or approaches, or helping bridge research findings into everyday practice.

Basic Science Posters

Poster #, Title + Submitter

1 **Effects of Transcranial Infrared Laser Stimulation on Cerebral Blood Flow in Bipolar Disorder: Acute and Cumulative Findings**
Acacia Nawrocik-Madrid - University of Texas at Austin Dell Medical School

2 **Predictors of Suicidality in 7-Year-Old Children with Autism Spectrum Disorder**
Adriana Desalos - University of Texas at Austin Dell Medical School

3 **A Window into aiTBS Response: Blood Biomarkers in Treatment-Naïve Adolescents with Depression**
Alejandro Banchs - University of Texas at Austin Dell Medical School

4 **Childhood Maltreatment Exposure Moderates the Effect of Hereditary Risk for Bipolar I Disorder on Brain Function During Reward Processing in Youth**
Alyssa Rosales - University of Texas at Austin Dell Medical School

5 **Sleep Difficulties and Depression Predict Irritability Independent of Other Mood Symptoms in Children of Bipolar Parents**
Ashley Lubben - UTHealth Houston

6 **Engagement of the Subcallosal Cingulate Cortex with Low-Intensity Focused Ultrasound: Dependence on Target and Intensity**
Brian Mickey - University of Utah

7 **Structural Integrity of White Matter and Functional Connectivity When Expecting Alcohol in Young Adults with Bipolar Disorder: a Placebo-Controlled Alcohol Administration DWI and FMRI Study**
Caitlin Rinehart - University of Texas at Austin Dell Medical School

8 **Primary care perspectives on management of individuals with TRD**
Caroline Hostetler - Compass Pathways, Inc

9 **Early Symptom Improvement As A Predictor of Remission Following Transcranial Magnetic Stimulation For Major Depressive Disorder**
Chloe Venter - Florida State University College of Medicine

Basic Science Posters, continued

10 **Acute Effects of aiTBS on Adolescent Cognition: Secondary Outcomes from A Pilot Trial**
Dharsan Selvakumar - University of Texas at Austin Dell Medical School

11 **Baseline depression and anxiety measures do not predict progression from suicidal ideation to suicide attempt: a three-method analysis of the NNDC Mood Outcomes Program**
Eric Monson - University of Utah

12 **Impact of bipolar disorder in trauma-exposed youth: A longitudinal investigation**
Erin Logue - University of Texas at Austin Dell Medical School

13 **Analytical Validation of Speaker Diarization and Role Assignment for Computational Speech Analysis in Clinical Settings**
Evelyn Vo - University of Wisconsin-Stout Polytechnic

14 **JOURNEY: Joint Outcomes and Understanding of Real-world Neurostimulation Effectiveness over Years — Longitudinal Symptom Trajectories During TMS for Treatment-Resistant Depression**
Giselli Scaini - UTHealth Houston

15 **Depression Assessment in Schizophrenia: Trait Depression as a Missing Gap**
Gustavo Dos Santos Alves Maria - UTHealth Houston

16 **Altered neural recruitment during a grip-force task in depression: A pilot fMRI study**
Ioanna Douka - University of Utah

17 **Longitudinal trend of suicidal ideation in young adults with autism and the impact of loneliness**
Ilsabella Reiser - University of Texas at Austin Dell Medical School

18 **Association Between Sleep Duration and Alcohol Use Among Pregnant Women: A Nationally Representative Study**
Jake Langevin - Florida State University College of Medicine

19 **Changes in ventral prefrontal-subcortical network connectivity during the course of remission from bipolar mania**
Jennifer Siegel-Ramsay - University of Texas at Austin Dell Medical School

20 **Extracting Speech Biomarkers from Clinical Conversations: Preliminary Results and Demonstration of Ambient Sensor Technology**
Jeremiah Joyce - Mayo Clinic

21 **PTSD and Suicidality, but not Depression, have Peripheral Immune Signatures Among Trauma-Exposed Adolescents**
John Leri - University of Texas at Austin Dell Medical School

22 **A Preliminary Analysis of the Discriminative Capacity of the Body Roundness Index, Conventional Anthropometrics, and Diet Quality for Identifying Suicide Risk at First Consultation in Major Depression**
Jose Carlos Gonzalez Cantu - Universidad Autónoma de Nuevo León

23 **A Prospective Observational Pilot Study: Psychological and Neuropsychological Predictors of Response to Repetitive Transcranial Magnetic Stimulation (rTMS) for Major Depressive Disorder**
Lauren Eide - Mayo Clinic

24 **Momentary social and emotional experiences as Predictors of Depression in Autistic Adolescents: An Ecological Momentary Assessment Study**
Lydia Salbilla - University of Texas at Austin Dell Medical School

Basic Science Posters, continued

24 **Momentary social and emotional experiences as Predictors of Depression in Autistic Adolescents: An Ecological Momentary Assessment Study**
Lydia Salbilla - University of Texas at Austin Dell Medical School

25 **Differential Acute Effects of Psilocybin and the Synthetic Cannabinoid JWH-018 During the Retrieval of True and False Memories**
Manoj Doss - University of Texas at Austin Dell Medical School

26 **Preferences and Concerns for Bipolar Depression Treatment: A Mixed-Methods, Multi-Perspective Pilot Study of Clinicians and Individuals with Lived Experience to Advance Shared Decision-Making in Mexico**
Manuel Gardea Resendez - Universidad Autónoma de Nuevo León

27 **Early Electroconvulsive Therapy in Severe First-Episode Depression: Clinical Rationale, Evidence Gaps, and a Research Agenda**
Marina Seixas Studart e Neves - UTHealth Houston

28 **Metabolic Correlates of Suicidal Ideation in a Longitudinal Cohort of Hospitalized Adults with Mood Disorders**
Mihai Bendea - UTHealth Houston

29 **When Stability Becomes the Risk: Peripartum Dilemma and Lamotrigine**
Olga Lopez - Mayo Clinic

30 **"Moodin"- a new brain protein uniquely targeted by chronic mood stabilizers treatment**
Rif El-Mallakh - University of Louisville School of Medicine

31 **Direct electrical stimulation of the ventral capsule and ventral striatum leads to acute antidepressant effects in patients with severe, treatment-refractory OCD**
Robert Seilheimer - University of Texas at Austin Dell Medical School

32 **Negative Affect Associations with Higher-Order Fear Generalization: The Role of Dysphoria, Intrusions, and Internalizing Psychopathology**
Samuel Cooper - University of Texas at Austin Dell Medical School

33 **The Relationships between Daily Self-Reported Sleep Characteristics and Mood State in Bipolar I Disorder**
Sera Pensoy - Mass General Brigham

34 **Lost in the Left DLPFC: Evaluating the Compounding Effects of Figure-8 TMS Coil Misalignment in Treating MDD**
Simon Shugar - University of Florida

35 **A Preliminary Exploratory Analysis of Spatial Patterns of Suicide Risk in First-Time Outpatients with Depressive Disorders Using Geographic Information Systems in Monterrey, Mexico**
Sofia Jezzini-Martinez - Universidad Autónoma de Nuevo León

36 **Duration of Hormonal Contraception Use on Brain Structure in Bipolar Disorder**
Sophie Buchmaier - University of Texas at Austin Dell Medical School

37 **Treadmill Exercise Ameliorates Inflammatory Pain-Induced Depressive-like Behaviors and Reestablishes ACC Synaptic Homeostasis in Mice**
Tianyi Zhao - Mayo Clinic

Basic Science Posters, continued

38 **Thyroid Hormone Augmentation as a Mood Stabilizer in Bipolar Disorder**
Umair Bhutto - University of Louisville School of Medicine

39 **Methylomic and Transcriptomic Signatures of Suicide Death in Postmortem Brains of Individuals with Bipolar Disorder**
Valeria Arredondo - UTHealth Houston

Clinical Programs Posters

Poster #, Title + Submitter

40 **Parenting Practices among Parents of US Youth Receiving Mood Disorder Treatment: Role of State Legal Context and Attitudes**
Aditya Sareen - Johns Hopkins

41 **OCD and Co-occurring Mood Outcomes After Electroconvulsive Therapy: An Updated Systematic Review**
Akhil Anand - Cleveland Clinic

42 **Real-world patient-reported outcomes in adults receiving zuranolone by timing of postpartum depression symptom onset**
Andrea Shafer - Biogen

43 **Rapid Onset of Antidepressant Effects Following Stanford Accelerated Intelligent Neuromodulation Therapy (SAINT): A Multi-Cohort Analysis**
Andrew Geoly - Magnus Medical

44 **Direct and Indirect Measures of Suicidality in Treatment-Naive Adolescents Receiving Accelerated Neuromodulation Therapy**
Angela Pham - University of Texas at Austin Dell Medical School

45 **Building a Digital Platform Providing Patient-Based Education Focused on Alcohol Use and Bipolar Disorders**
Bilge Nur Ozdemir - Mayo Clinic

46 **Inflammatory Biomarker Reverse Triiodothyronine (rT3) and its Association with the Neurovegetative Index of Melancholia in Bipolar Disorder**
Bishnu Pathak - Mayo Clinic

47 **Large Language Models in Bipolar Disorder and Major Depressive Disorder: The Technological Arc**
Cecilia Torres - Universidad Autónoma de Nuevo León

48 **Insulin Resistance, Brain Function, and Cognition in Bipolar Disorder Project with the BD2 Integrated Network**
Christopher Busby - University of Texas at Austin Dell Medical School

49 **Developing a Patient-Centered Psychotherapy Experience Assessment for Mood Disorders**
D. Gage Jordan - Ohio State University

50 **Clinical phenotype, metabolic profile and treatment response among women with bipolar disorder and polycystic ovary syndrome**
Dania García - Universidad Autónoma de Nuevo León

51 **Tracking depressive symptoms following accelerated intermittent theta burst stimulation in treatment-naive adolescents**
Daniella Santos - University of Texas at Austin Dell Medical School

Clinical Programs Posters, continued

52 **From Peripartum to Midlife Transition: Long-Term Risk of Mood and Psychotic Disorders Following Peripartum Mental Disorders**
Deniz Ceylan - Mayo Clinic

53 **Elevated Monocytes as Blood Cell-Based Inflammatory Markers in First-Episode Mania Compared with First-Episode Psychosis**
Dina Ali - Mayo Clinic

54 **Early Intervention Through Integration: How Non-Clinical Roles Reduce Crisis Mode in Integrated Youth Services**
Elizabeth Martin - University of Texas at Austin Dell Medical School

55 **The New NNDC Psychotherapy for Mood Disorders Task Group: Overview of Current Initiatives**
Emily Standish - Western Michigan University Homer Stryker MD School of Medicine

56 **Sex Differences in Childhood Trauma Types and Intentionality: Findings from the Texas Childhood Trauma Research Network (CTRN)**
Erin Richardson - University of Texas at Austin Dell Medical School

57 **Augmenting cognitive behavioral therapy for major depressive disorder with transcranial infrared laser stimulation: a randomized controlled trial**
Francisco Gonzalez-Lima - University of Texas at Austin Dell Medical School

58 **Long Term Lithium Exposure and Chronic Kidney Disease in the Elderly with Bipolar Disorder: A Systematic Review and Meta-Analysis**
Hammza Jabbar Abdl Sattar Hamoudi - UTHealth Houston

59 **Longitudinal Inflammatory Phenotyping Identifies Pretreatment Platelet-to-Lymphocyte Ratio Trajectory as a Candidate Prognostic Marker of Ketamine/Esketamine Treatment Course**
Hossam Ali - Mayo Clinic

60 **Behavioral strategies to accomplish challenging imaging protocols in children and adolescents with mood disorders**
James Brasic - Johns Hopkins

61 **Youth and Parent Perspectives on Standard and Truncated Neuronavigated aiTBS for Treatment Naive Adolescent Depression: A Qualitative Study**
Joseph McGrath - University of Texas at Austin Dell Medical School

62 **The HELP Program: Facilitating Early Support of Healthcare Workers at Risk for Depression Following Traumatic Clinical Events Using an Established Enterprise-Wide Peer Support Program**
Kalei Lopez - Mayo Clinic

63 **It Takes a Team: A Multi-Perspective Exploration of Mental Health Resource Needs in Youth Sports**
Keira Bennett - Johnson Depression Center, University of Colorado Anschutz

64 **Association Between Childhood Trauma and Resilience in Youth at High Familial Risk for Bipolar Disorder**
Leticia Barbetta - University of Texas at Austin Dell Medical School

65 **Catatonia as an Underrecognized Neuropsychiatric Manifestation of Reversible Cerebral Vasoconstriction Syndrome**
Madan Subheeswar - University of Louisville School of Medicine

Clinical Programs Posters, continued

66 **Electroconvulsive Therapy Across Pregnancy and the Postpartum Period in Bipolar I Disorder: A Case Report and Review of Perinatal Relapse Risk**
Nicolas Abchee - University of Florida

67 **Prescriber knowledge, skills, and attitudes of patient-reported outcome measures for depressive and anxiety symptoms**
Nithya Warrier - University of Cincinnati

68 **Human-centered design for inpatient psychiatry: Technical feasibility and patient acceptability of real-time wearable-based safety checks**
Peter Iacobelli - UTHealth Houston

69 **Effects of Dextromethorphan-Bupropion (45mg/105mg) in Participants with Major Depressive Disorder and Anxious Distress**
Phillip Lai - Axsome Therapeutics, Inc.

70 **Lower synaptic density in mood circuitry underlies depression in Parkinson's disease**
Salih Cayir - UTHealth Houston

71 **Safety and Efficacy of Full and Half-Dose fMRI-Guided Accelerated Theta Burst TMS in Treatment-Naïve Adolescent Depression**
Sean O'Sullivan - University of Texas at Austin Dell Medical School

72 **Race and Gender Shape Legal Outcomes in Public Defender Clients with Symptoms of Mental Illness**
Shireen Husami - Western Michigan University Homer Stryker MD School of Medicine

73 **Postpartum Psychotic Illness With Persistent Catatonia Mimicking Autoimmune Encephalitis: Delayed Recovery Associated With Bilateral Electroconvulsive Therapy**
Shivani Malavia - UTHealth at Houston

74 **Anti-Anhedonic Effects of Dextromethorphan-Bupropion Mediate Improvements in Functioning and Quality of Life in Major Depressive Disorder**
Sucharita Somkuwar - Axsome Therapeutics, Inc.

75 **Phase 3 Topline Results of DT120 (lysergide) in Major Depressive Disorder**
Todd Solomon - Definium Therapeutics

76 **Long-Term Patient-Reported Outcomes with Zuranolone for Postpartum Depression: A Real-World Observational Study**
Tonya N. Taylor - Biogen


77 **DATAd: A New Communication and Tracking System for Treatment-Resistant Depression**
Vitaliy Voytenko - Western Michigan University Homer Stryker MD School of Medicine

78 **Family Cultural Context, Trauma Exposure, and Resilience Among Hispanic Youth**
Yasmin Mohamoud - University of Texas at Austin Dell Medical School


79 **Timing of Evidence-Based Psychotherapy Relative to Plasticity-Inducing Treatments in Depression: A Scoping Review and Unifying Framework**
Zachary Springs - UC Davis

Facility Map - Texas Union

First Level




Second Level (ground level)




Facility Map - Texas Union

Third Level



Fourth & Fifth Levels



NNDC Upcoming Events — Join us in 2027!

We're actively in the planning process with more information available soon!



APA Networking Reception
May 1, 2027 @ 5th & MAD in NYC



2027 Best Practices for Mood Disorders
September 23-25, 2027 in Denver, CO



2027 NNDC Annual Conference
December in Tallahassee, FL

LET'S CONNECT!

NEWS, EVENTS, UPDATES AND MORE!








GIVE US A FOLLOW!

WANT TO BE FEATURED?

Email Courtney Soule at csoule@nndc.org



LEARN MORE AT NNDC.ORG